TOPICAL THERAPY WITH THE USE OF 0.1% METHYLPREDNISOLONE ACEPONATE IN THE COMPLEX TREATMENT OF ATOPIC DERMATITIS IN CHILDREN


DOI: https://dx.doi.org/10.18565/pharmateca.2018.1.43-47

I.V. Khamaganova, A.A. Tsykin

Department of Skin Diseases and Cosmetology FAPE N.I. Pirogov Russian National Research Medical University (RNRMU), Moscow, Russia
The article presents an analysis of literature data on the rationale for the use of methylprednisolone aceponate (Advantan, Bayer) in the treatment of children with atopic dermatitis. The study was aimed to the evaluation of the efficacy and safety of the use of various dosage forms of methylprednisolone aceponate in the complex therapy of children suffering from atopic dermatitis. Methylprednisolone aceponate is approved for use in children from 4 months of age. The undoubted advantages of the drug include the possibility of applying to the open skin areas, including the face. The use of 0.1% methylprednisolone aceponate allows to choose the optimal dosage form for the appropriate age group. The emulsion was applied to inflammation foci in children aged 4 months to 3 years, as well as in the acute inflammatory process and localization in the face in other age groups. The cream was prescribed for acute and subacute inflammation. Ointment was recommended for chronic inflammation. Oily ointment was prescribed for prolonged chronic inflammation, accompanied by skin, pronounced lichenification and thickening of the skin. Treatment was not accompanied by side effects. The efficacy and safety of topical application of 0.1% methylprednisolone aceponate in children is demonstrated.
Keywords: atopic dermatitis, methylprednisolone aceponate, medicinal forms of topical agents, skin features in children

About the Autors


Corresponding author: I.V. Khamaganova – MD, Prof. at the Department of Skin Diseases and Cosmetology FAPE N.I. Pirogov Russian National Research Medical University (RNRMU), Moscow, Russia; tel. 8 (495) 770-09-50, e-mail: irina.khamaganova@gmail.com


Бионика Медиа